Friday, 23 Oct 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US
Stabilizing Foreign Investment: China's Comprehensive Action Plan for 2025
Policy / Regulatory

Stabilizing Foreign Investment: China’s Comprehensive Action Plan for 2025

February 20, 2025
Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research
CompanyDeals

Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research

February 20, 2025
Innogen Pharmaceutical Launches Efsubaglutide Alfa for Type 2 Diabetes in China
CompanyDrug

Innogen Pharmaceutical Launches Efsubaglutide Alfa for Type 2 Diabetes in China

February 20, 2025
Bayer's AskBio Receives RMAT Designation for AB-1005 in Parkinson's Disease
CompanyDrug

Bayer’s AskBio Receives RMAT Designation for AB-1005 in Parkinson’s Disease

February 20, 2025
Phanes Therapeutics Doses First Patient in Peluntamig Study for SCLC and NEC
CompanyDrug

Phanes Therapeutics Doses First Patient in Peluntamig Study for SCLC and NEC

February 20, 2025
Epitopea and Merck Partner to Identify Cryptigen Tumor Antigens
CompanyDeals

Epitopea and Merck Partner to Identify Cryptigen Tumor Antigens

February 20, 2025
Boehringer Ingelheim's Zongertinib NDA Accepted by FDA for HER2-Mutated NSCLC
CompanyDrug

Boehringer Ingelheim’s Zongertinib NDA Accepted by FDA for HER2-Mutated NSCLC

February 20, 2025
Hepalink Pharmaceutical's H1710 Heparanase Inhibitor Approved for Phase I Study
CompanyDrug

Hepalink Pharmaceutical’s H1710 Heparanase Inhibitor Approved for Phase I Study

February 20, 2025
Henlius Biotech's Avastin Biosimilar Hanbeitai Approved in Bolivia
CompanyDrug

Henlius Biotech’s Avastin Biosimilar Hanbeitai Approved in Bolivia

February 20, 2025
Astellas Pharma's Xospata Wins Regular NMPA Approval for FLT3-Mutated AML
CompanyDrug

Astellas Pharma’s Xospata Wins Regular NMPA Approval for FLT3-Mutated AML

February 20, 2025
Hanx Biopharmaceuticals' HX009 Receives NMPA Clearance for TNBC Study
CompanyDrug

Hanx Biopharmaceuticals’ HX009 Receives NMPA Clearance for TNBC Study

February 20, 2025
Huadong Medicine's MediBeacon TGFR System Approved by NMPA for GFR Measurement
CompanyMedical Device

Huadong Medicine’s MediBeacon TGFR System Approved by NMPA for GFR Measurement

February 20, 2025
1 2 … 8 9 10 11 12 … 26 27
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up